Trending Up0.0450 (2.0737%)
  • Bid / Lots
    2.2200/ 2
  • Ask / Lots
    2.2800/ 5
  • Open / Previous Close
    2.1740 / 2.1700
  • Day Range
    Low 2.1700
    High 2.2199
  • 52 Week Range
    Low 1.2732
    High 4.4783
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.17
09:33 ET118902.17
09:50 ET1002.1999
10:04 ET10002.19
10:08 ET197112.1999
10:09 ET1002.18
10:13 ET2002.1969
10:31 ET7002.1801
10:51 ET2002.1899
11:02 ET11952.1877
11:07 ET2002.1803
11:16 ET2002.1996
11:45 ET9042.1816
11:50 ET1002.1965
12:06 ET63002.18
12:08 ET11002.18
12:10 ET4002.18
12:12 ET1002.18
12:15 ET5002.18
12:24 ET2002.18
12:26 ET7002.1999
12:28 ET2002.18
12:30 ET2002.18
12:32 ET2002.18
12:33 ET4002.1965
12:35 ET8002.1979
12:37 ET4002.195
12:42 ET1002.19
12:44 ET1002.1979
12:51 ET31002.195
01:02 ET7002.19
01:18 ET29922.1999
01:22 ET1002.2
01:29 ET20002.2
01:31 ET1002.21
01:33 ET1002.2
01:36 ET2002.2
01:40 ET4002.2
01:44 ET2002.2
01:51 ET16952.2
01:58 ET2002.2
02:30 ET1002.2199
02:45 ET17032.21
02:48 ET4002.215
03:15 ET2002.215
03:17 ET1002.21
03:32 ET3002.2199
03:39 ET1502.2181
03:44 ET1002.21
03:57 ET4002.215
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBPTH
Bio Path Holdings Inc
United StatesCHEK
Check Cap Ltd
United StatesNNVC
NanoViricides Inc
United StatesONTX
Onconova Therapeutics Inc
United StatesGLMD
Galmed Pharmaceuticals Ltd
United StatesRAPH
Raphael Pharmaceutical Inc
As of 2023-01-29

Company Information

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company. It utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.

Contact Information

4710 Bellaire Blvd Ste 210BELLAIRE, TX, United States 77401-4505


Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
Peter Nielsen
Director of Investor Relations, Secretary, Director
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Aline Sherwood

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.